suPAR – biomarkör för bättre triageEarly Risk Recognition in Acute Care Triage – think suPARnostic®

ELECTRA-BOX och ViroGates ställer ut på SWEETs och sponsrar en föreläsning om suPAR

Early Acute Triage in the Emergency Department (ED) is important to improve selection of patients for different levels of medical attention. Patients with subtle symptoms can be difficult to evaluate.

The biomarker suPAR (soluble urokinase plasminogen activating receptor) is a blood marker of disease presence, severity and prognosis. Due to these abilities, suPAR is used in acute care triage to support clinical decisions such as; whether to admit or patient or not. suPAR levels can be measured with the new CE IVD test suPARnostic® Quick Triage.
suPAR is associated with disease severity and mortality in patients suffering from a single disease or co-morbidities (ref.1,2) and implementation as an aid to current Acute Triage has shown to have an impact on readmission rates and patient handling in the ED along with potential savings on hospital budget (ref. 3,4). A low level of suPAR in addition to existing triage parameters can aid triage decisions regarding non-admission while patients with an elevated suPAR level (e.g., above 5 ng/ml) should receive a high level of clinical attention.
With a sample of venous blood the test can be performed in just 30 minutes using the suPARnostic® Quick Triage Point of Care Device and results collected with the Test Reader imported via a PC into to the Hospital LIS database.

Do you want to hear more?
Join the oral presentation by Dr. Jesper Eugen-Olsen, Denmark, March 16, at 12.40
Or go to the ElectraBox/ViroGates booth on March 16-17.

The suPARnostic® Triage test is developed and marked by the Danish Biotech Company ViroGates. Based on the study by Haupt and coworkers (ref. 1) Copenhagen University Hospital Hvidovre, Denmark, has implemented suPARnostic® in their clinical routine testing. Analysis of the first 4343 consecutively admitted patients showed that:

Patients who died within 30 days of follow-up had a higher mean suPAR (8 ng/ml) compared to patients who survived (3.7 ng/ml, p<0.0001). The AUC of suPAR for 30-day mortality was 0.84 (95% CI: 0.81-0.86). suPAR is strongly and significantly associated with risk of re-admittance within 30 days of discharge (p<0.0001).

A similar study carried out at Hillerød Hospital including 5992 acute care patients confirmed the results (e.g. AUC for 30-day mortality 0.85) (ref 2).

References
1. Haupt TH et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care. 2012 Jul 23;16(4):R130. doi: 10.1186/cc11434.
2. Østervig RM et al. suPAR a future Prognostic Biomarker in Emergency Medicine, Prize Awarded Poster selected for full audience presentation at 6th DEMC conference, Odense Denmark, Nov 2014.
3. Data on file at Hvidovre University Hospital, Denmark.
4. MEMO “Systematic use of suPARnostic® in Acute Medical Care : economic savings potential” by Health Economist Jens Olsen.

okänt